CRYO CELL INTERNATIONAL INC
CCELNYSEHealthcare · Services-Misc Health & Allied Services, NEC · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $31.6M | $32.0M | $31.3M | $30.3M | $28.9M | $31.1M |
| Operating income | $482,394 | $3.5M | −$12.3M | $4.0M | $4.0M | $7.7M |
| Net income | −$2.4M | $402,095 | −$9.5M | $2.8M | $2.1M | $3.6M |
| Total assets | $61.7M | $64.7M | $61.2M | $64.9M | $60.7M | $46.2M |
| Total liabilities | $80.3M | $77.9M | $72.3M | $66.4M | $56.5M | $48.9M |
| Equity | −$18.6M | −$13.2M | −$11.0M | −$1.5M | $4.2M | −$2.7M |
| EPS (diluted) | $-0.30 | $0.05 | $-1.14 | $0.33 | $0.25 | $0.45 |
| Shares out. | 8.1M | 8.3M | 8.4M | 8.5M | 7.6M | 7.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 1.5%
- Net margin
- −7.7%
- Return on equity
- 13.1%
- Return on assets
- −3.9%
- Return on capital (ROCE)
- 1.2%
- Liabilities / assets
- 130.1%
- Debt / equity
- —
- Book value / share
- $-2.30
- Revenue growth (YoY)
- −1.3%
- Net income growth (YoY)
- −704.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -3.07distress
- Accruals / assets
- −12.8%clean
- Beneish M-Score
- -3.21normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 3 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Apr 14, 2023
- NT 10-Qmissed a reporting deadline ↗Oct 18, 2022
- NT 10-Qmissed a reporting deadline ↗Apr 15, 2010
- NT 10-Qmissed a reporting deadline ↗Apr 15, 2003
- NT 10-Qmissed a reporting deadline ↗Oct 16, 2002
- NT 10-Qmissed a reporting deadline ↗Jul 16, 2002
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Camac Partners, LlcActivist (13D)Mar 25, 2026
- Cdmj Nyberg Family TrustPassive (13G)Dec 27, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Taymans Jill MOfficer — VP Finance, CFO | May 28, 2026 | Option exercise | 7,500 | $3.10 |
| Portnoy DavidOfficer — Chairman, Co-CEO | Nov 20, 2025 | Grant | 289 | $4.00 |
| Portnoy DavidOfficer — Chairman, Co-CEO | Nov 17, 2025 | Grant | 1,429 | $4.00 |
| Portnoy DavidOfficer — Chairman, Co-CEO | Nov 10, 2025 | Grant | 1,026 | $4.18 |
| Portnoy DavidOfficer — Chairman, Co-CEO | Oct 31, 2025 | Grant | 4,666 | $4.45 |
| Portnoy DavidOfficer — Chairman, Co-CEO | Sep 16, 2025 | Buy | 6,449 | $4.46 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9,834 | 1.3 | +40.2% |
| Apr 30, 2026 | 7,016 | 1.0 | -11.6% |
| Apr 15, 2026 | 7,936 | 1.0 | -27.4% |
| Mar 31, 2026 | 10,927 | 1.0 | +91.3% |
| Mar 13, 2026 | 5,712 | 1.0 | -35.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Regulation FD disclosureMay 8, 2026
- Delisting / listing-standard notice · Regulation FD disclosureMar 12, 2026
- Other material eventNov 12, 2025
- Entered a material agreement · New financial obligationOct 23, 2025
- Other material eventSep 10, 2025
- Terminated a material agreementMay 22, 2025
- Other material eventMay 8, 2025
- Shareholder voteOct 31, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.